American Diabetes Association
Supplemental_Material_Nov_Com_(final)19 1.pdf (385.23 kB)

Home Use of Mini-Dose Glucagon As a Novel Treatment for Hypoglycemia Following Repeated, Prolonged Fasts in Type 1 Diabetes During Ramadan

Download (385.23 kB)
posted on 2022-03-03, 15:07 authored by Metab A Algeffari, Sufyan Hussain, Turki A Almogbel, Mansour S Alsharidah, Habibah A Alghadouni, Farid M Mahmood
We determined the efficacy of self-administered subcutaneous mini-dose glucagon (MDG) to treat fasting-induced hypoglycemia in type 1 diabetes (T1D).
Research Design and Methods
4-week randomized, controlled crossover trial (2-week MDG or 2-week oral glucose tablets (OG, control)) involving 17 adults with T1D during Ramadan.
As compared to OG, MDG demonstrated a significant higher change in blood glucose from baseline to 30 minutes (∆t30, P<0.001) and 1 hour (∆t60, P=0.02). The efficacy of MDG was preserved following ≥8 hours fasting with significantly higher ∆t30 in MDG (P=0.01). Over the entire two-week, MDG period had increased time in 70-180 mg/dL (P=0.009) and less time<70 mg/dL (P=0.04). MDG use resulted in higher completion of fasts as compared OG (P<0.001).
MDG administration is an effective alternative to OG for prevention and treatment of fasting-induced hypoglycemia, offering improved glycemic control and promoting successful completion of prolonged fasts.


The project was supported by grants from Qassim University (Agreement #5389-med-2019-2-2-I)